Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
In this prospective, randomized, open-label, parallel group trial, the safety and efficacy of
insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with basal insulin
once or twice daily plus pre-prandial insulin after 16 weeks of treatment in patients with
type 1 diabetes. This trial will enable assessment of the clinically relevant endpoint of a
change in HbA1c and Time in Range (TIR).
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University